Status:
COMPLETED
Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty
Lead Sponsor:
Massachusetts Eye and Ear Infirmary
Conditions:
Fuchs' Endothelial Dystrophy
Cataract
Eligibility:
All Genders
50-70 years
Phase:
EARLY_PHASE1
Brief Summary
Primary aim of the study is to determine whether a rho kinase inhibitor, Netarsudil, can speed corneal clearance after DWEK. Secondary aim of the study is to investigate whether patient factors, such ...
Detailed Description
Spontaneous corneal clearance after Descemetorhexis without keratoplasty (DWEK) has been documented in several previous trials. One of the largest cohorts at Massachusetts Eye and Ear Infirmary demons...
Eligibility Criteria
Inclusion
- Cataract in both eyes
- Fuchs endothelial dystrophy in both eyes
Exclusion
- History of ocular surgery in one eye and not the other
- History of significant ocular trauma/burn in one eye and not the other
- Inability to provide informed consent
- Inability to undergo eye surgery
- Inablity to use eye drops reliably
Key Trial Info
Start Date :
October 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04057053
Start Date
October 2 2018
End Date
December 20 2020
Last Update
January 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States, 02114